Website: https://www.procegence.com/
We’ve seen first-hand the cost of scale-up failures, tech transfer delays, and process inefficiencies. Procegence provides modeling and simulation services to solve these challenges across the full development lifecycle: process and product development, equipment selection and characterization, process optimization, and CMC.
Our consulting and model building services span in silico modeling, regulatory support, digitalization, risk assessment with changing process parameters, and device, facility, and equipment design. The output is actionable intelligence that can be applied to biopharma as well as adjacent industries like fine chemicals, food and beverage, and energy.
With on-demand services and fast turnaround, Procegence helps organizations reduce time, cost, and risk while improving yield, quality, and equipment performance.
As your Simulation-as-a-Service partner, we provide high-fidelity mechanistic and hybrid modeling tailored to your specific process, equipment, and regulatory context.
We can support your work at every stage, from early process development through tech transfer, scaleup, and commercialization, bringing deep expertise in predictive modeling, digital twins, and CMC regulatory preparation.
One of the biggest barriers to adoption of modeling & simulation is the concern about building infrastructure and expertise.
Simulation-as-a-Service is Procegence’s approach to providing customized, on-demand modeling & simulation, eliminating the need for companies to build that expertise in-house.
What does a 12% improvement in product yield look like at biopharmaceutical scale? For one leading biopharma company running high-volume mAb bioprocessing, it translated to ~$20 million per year in additional revenue - without a single piece of new equipment. Working within the constraints of an existing brownfield GMP manufacturing setup, the Procegence team applied high-fidelity simulations to do what traditional DOE-based optimization simply couldn't, with three main outcomes:
Spray drying has been used for decades to solve one problem well: improving bioavailability for poorly soluble small molecules.
An executive summary featuring contributions from Procegence Founder, Nima Yazdanpanah, makes the case that, with GLP-1 agonists and oral peptide therapies pushing lyophilization capacity to its limits, spray drying is becoming a viable alternative.
Three realities are shaping what comes next:
Every project begins with understanding a company’s goals and the specific business problems that are top of mind. From there, we define the scope, timeline, and cost. Our collaborative business workflow ensures alignment and transparency at every step:
Reach out to learn more or to schedule a discovery call with our team.